Reishi Mushroom: Are you a health professional? - CancerChoices



Reishi mushroom is a natural product that may enhance immunity and response to chemo/radiotherapy, improve quality of life, and manage some side effects. 

Are you a health professional?

This section does not replicate the other information on this topic but provides additional details or context most relevant to professionals.

Modes of action

Studies suggest that the anti-tumor activities of G. lucidum polysaccharide (GLPS) are mediated by its immunomodulatory, anti-angiogenic, and cytotoxic effects. GLPS affects immune cells and immune-related cells including B lymphocytes, T lymphocytes, dendritic cells, macrophages, and natural killer cells.1Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. American Journal of Chinese Medicine. 2011;39(1):15-27. 

Network pharmacology revealed that key targets of G. lucidum against endometrial cancer were primarily associated with the Rap1 signaling pathway.2Shi M. The efficacy of Ganoderma lucidum extracts on treating endometrial cancer: a network pharmacology approach. Reproductive Sciences. 2024 Jul;31(7):1881-1894.

Androgen receptor, nuclear factor-kappa B, activator protein-1, p53 and 14-3-3 are reportedly involved in the anticancer properties of G. lucidum triterpenoids.3Wu GS, Guo JJ et al. Anti-cancer properties of triterpenoids isolated from Ganoderma lucidum—a review. Expert Opinion on Investigtional Drugs. 2013 Aug;22(8):981-92. 

Ganoderic acids might exert their cytotoxicity by altering proteins involved in cell proliferation and/or cell death, carcinogenosis, oxidative stress, calcium signaling, and ER stress.4Yue QX, Song XY et al. Effects of triterpenes from Ganoderma lucidum on protein expression profile of HeLa cells. Phytomedicine. 2010 Jul;17(8-9):606-13.

More on safety

One cell study found toxic effects of reishi mushrooms on human leukocytes.5Gill SK, Rieder MJ. Toxicity of a traditional Chinese medicine, Ganoderma lucidum, in children with cancer. Canadian Journal of Clinical Pharmacology. 2008 Summer;15(2):e275-85. and another study found that “both submerge-cultured intracellular GLP and fruiting body GLP can stimulate the growth of human carcinoma cell lines lacking functional p53, such as HCT-116 p53(-/-), Saos-2, H1299, HL-60, MDA-MB-157. Conversely, the two GLPs inhibit all other assayed cells with functional p53.”6Zhang J, Chen JM et al. Inhibitor or promoter? The performance of polysaccharides from Ganoderma lucidum on human tumor cells with different p53 statuses. Food & Function. 2016 Apr;7(4):1872-5.

Preclinical evidence

The strongest preclinical studies for various types of cancer are presented here. Clinical evidence is presented in How can reishi mushroom help you? What the research says ›

Improving treatment outcomes

Cancer as a whole

Enhanced response to chemotherapy

    • Nanoparticles loaded with G. lucidum polysaccharide at 6 µg/ml and chitosan/sodium tripolyphosphate (mass) ratio of 5.5 had significantly greater cytotoxic effects on tumor cells.7Li N, Hu YL et al. Preparation, characterisation and anti-tumour activity of Ganoderma lucidum polysaccharide nanoparticles. Journal of Pharmacy and Pharmacology. 2010 Jan;62(1):139-44.
      Bile duct cancer cancer (cholangiocarcinoma)
      Bladder cancer
      • Reishi inhibited the viability and growth of human urothelial cells.12Yuen JW, Gohel MD, Au DW. Telomerase-associated apoptotic events by mushroom ganoderma lucidum on premalignant human urothelial cells. Nutrition and Cancer. 2008;60(1):109-19.
      • Reishi extracts inhibited the growth of human urothelial cells, and ethanol extracts had a stronger growth inhibition effect than water extracts.13Lu QY, Jin YS et al. Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro. Cancer Letters. 2004 Dec 8;216(1):9-20.

      Blood cancers

      Brain and nervous system cancers: tumor response 
      • Anaplastic meningioma: Reishi produced lower tumor volume, less tumor cell proliferation, and longer survival in rats.16Das A, Alshareef M et al. Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2020 Jul;22(7):1138-1145.
      • Glioma: Reishi produced slower tumor development and longer survival in rats.17Wang C, Shi S et al. Antitumor and immunomodulatory activities of Ganoderma lucidum polysaccharides in glioma-bearing rats. Integrative Cancer Therapies. 2018 Sep;17(3):674-683.
      • Glioblastoma: Ganoderic acid A isolated from reishi mushrooms inhibited human glioblastoma cell growth and invasion/migration and promoted apoptosis and autophagy.18Cheng Y, Xie P. Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway. Journal of Biochemical and Molecular Toxicology. 2019 Nov;33(11):e22392.
      • Neuroblastoma: Ganoderic acid isolated from reishi mushrooms exhibited downregulation in Notch-1 mRNA expression and inhibited proliferation, viability, and ROS activity in neuroblastoma cells.19Gill BS, Navgeet, Kumar S. Antioxidant potential of ganoderic acid in Notch-1 protein in neuroblastoma. Molecular and Cellular Biochemistry. 2019 Jun;456(1-2):1-14.
      Breast cancer: tumor response and less cell invasion, migration and metastasis

      Colon cancer: improved sensitivity to 5FU

      Gynecological cancer: tumor response in combination with cisplatin

      Liver cancer: tumor response

      Lung cancer: tumor response and reduce mobility

      Ovarian cancer: tumor response

      Prostate cancer: less adhesion and migration

      • Prostate cancer: less adhesion and migration of highly invasive prostate cancer cells32Sliva D. Ganoderma lucidum (reishi) in cancer treatment. Integrative Cancer Therapies. 2003 Dec;2(4):358-64.

      Optimizing your terrain

      Managing side effects and promoting wellness: preclinical evidence 

      Blood-related side effects

      Cardiovascular symptoms

      Changes in appetite

      • Better appetite and general health in rats38Wang CZ, Basila D et al. Effects of ganoderma lucidum extract on chemotherapy-induced nausea and vomiting in a rat model. American Journal of Chinese Medicine. 2005;33(5):807-15.

      Gastrointestinal effects

      Other chemotherapy and radiotherapy side effects

      Reducing cancer risk

      Bladder cancer: tumor inhibition

      Colorectal cancer: less carcinogenesis 

      Prostate cancer: inhibition of premalignant cells

      Skin cancer: fewer tumors and longer latency

      Helpful links for professionals

      National Cancer Institute logo

      Subscription required

      This table summarizes the evidence of interactions with reishi (Lingzhi) and turkey tail (Yunzhi) mushrooms and components with 17 chemotherapy drugs: Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in clinical studies ›
      From Lam CS, Cheng LP, Zhou LM, Cheung YT, Zuo Z. Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review. Chinese Medicine. 2020 Jul 25;15:75.

      Keep reading about reishi mushroom

      Authors

      Maria Williams

      Research and Communications Consultant
      View profile

      Maria Williams is a research and communications consultant who brings over 15 years’ experience in research, consumer education, and science communication to CancerChoices. She has worked primarily in public health and environmental health.

      Maria Williams Research and Communications Consultant

      Laura Pole, MSN, RN, OCNS

      Senior Clinical Consultant
      View profile

      Laura Pole is senior clinical consultant for CancerChoices. Laura is an oncology clinical nurse specialist who has been providing integrative oncology clinical care, navigation, consultation, and education services for over 40 years. She is the co-creator and co-coordinator of the Integrative Oncology Navigation Training at Smith Center for Healing and the Arts in Washington, DC. Laura also manages the “Media Watch Cancer News That You Can Use” listserv for Smith Center/Commonweal. In her role as a palliative care educator and consultant, Laura has served as statewide Respecting Choices Faculty for the Virginia POST (Physician Orders for Scope of Treatment) Collaborative as well as provided statewide professional education on palliative and end-of-life care for the Virginia Association for Hospices and Palliative Care.

      For CancerChoices, Laura curates content and research, networks with clinical and organizational partners, brings awareness and education of integrative oncology at professional and patient conferences and programs, and translates research into information relevant to the patient experience as well as clinical practice.

      Laura sees her work with CancerChoices as a perfect alignment of all her passions, knowledge and skills in integrative oncology care. She is honored to serve you.

      Laura Pole, MSN, RN, OCNS Senior Clinical Consultant

      Nancy Hepp, MS

      Lead Researcher
      View profile

      Ms. Hepp is a researcher and communicator who has been writing and editing educational content on varied health topics for more than 20 years. She serves as lead researcher and writer for CancerChoices and also served as the first program manager. Her graduate work in research and cognitive psychology, her master’s degree in instructional design, and her certificate in web design have all guided her in writing and presenting information for a wide variety of audiences and uses. Nancy’s service as faculty development coordinator in the Department of Family Medicine at Wright State University also provided experience in medical research, plus insights into medical education and medical care from the professional’s perspective.

      Nancy Hepp, MS Lead Researcher

      Reviewer

      Andrew Jackson, ND

      Research Associate
      View profile

      Andrew Jackson, ND, serves as a CancerChoices research associate. As a naturopathic physician practicing in Kirkland, Washington, he teaches critical evaluation of the medical literture at Bastyr University in Kenmore, Washington. His great appreciation of scientific inquiry and the scientific process has led him to view research with a critical eye.

      Andrew Jackson, ND Research Associate

      Last update: May 8, 2024

      Last full literature review: June 2021

      CancerChoices provides information about integrative in cancer care, a patient-centered approach combining the best of conventional care, self care and evidence-informed complementary care in an integrated plan cancer care. We review complementaryin cancer care, complementary care involves the use of therapies intended to enhance or add to standard conventional treatments; examples include supplements, mind-body approaches such as yoga or psychosocial therapy, and acupuncture therapies and self-care lifestyle actions and behaviors that may impact cancer outcomes; examples include eating health-promoting foods, limiting alcohol, increasing physical activity, and managing stress practices to help patients and professionals explore and integrate the best combination of conventionalthe cancer care offered by conventionally trained physicians and most hospitals; examples are chemotherapy, surgery, and radiotherapy and complementary therapies and practices for each person.

      Our staff have no financial conflicts of interest to declare. We receive no funds from any manufacturers or retailers gaining financial profit by promoting or discouraging therapies mentioned on this site.

      Learn more

      Health professional comment

      We invite health professionals to contribute expertise or send us questions.

      "*" indicates required fields

      Please share your thoughts about content on the CancerChoices website. If you have a correction for us to consider, or additional information to add, please include references and links if possible.

      References[+]